← Oncology Approval Tracker

FDA DECISION ·

Keytruda

pembrolizumab · Merck Sharp & Dohme

Accelerated approvalNew or expanded indicationTumor mutational burden-high solid tumors
Open LinkedIn brief ↓

1 min read · estimated

Sources

LATER FDA ACTION

Traditional approval granted on Oct 16, 2026

FDA Project Confirm ↗

APPROVED USE

What FDA approved

Adults and children with unresectable or metastatic solid tumors with at least 10 mutations per megabase on an FDA-approved test, following progression on prior treatment when no satisfactory alternatives remained.

LAMPGEN ANALYSIS

Why it matters

Made tumor mutational burden a cross-tumor selection marker for immunotherapy under accelerated approval.

What research teams should watch

Record the assay, measured burden, prior treatment and available alternatives before matching the historical label.

PRIMARY RECORDS

Sources